Efficacy of Dual Antiplatelet Therapy After Lacunar versus Non-Lacunar Syndromes in the POINT Trial

被引：0
|
作者：
Heidari, Parisa
Seitz, Alison
Liberman, Ava
Navi, Babak B.
Kamel, Hooman
机构：
来源：
STROKE | 2024年 / 55卷
关键词：
D O I：
10.1161/str.55.suppl_1.WP238
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
WP238
引用
收藏
页数：2
相关论文
共 50 条
  • [21] TIME COURSE OF COGNITIVE FUNCTIONING DURING THE FIRST YEAR AFTER ISCHEMIC NON-LACUNAR STROKES IN PATIENTS WITH ATRIAL FIBRILLATION
    Delva, M. Yu.
    Zayets, V. V.
    Chekalina, N. I.
    Delva, I. I.
    WORLD OF MEDICINE AND BIOLOGY, 2024, 89 (03): : 52 - 56
  • [22] Is There Still a Role for Dual Antiplatelet Therapy in the Secondary Prevention of Lacunar Stroke (vol 54, pg 2251, 2023)
    Shoamanesh
    STROKE, 2023, 54 (11) : E493 - E493
  • [23] Letter by Gutierrez Regarding Article, "Dual Antiplatelet Therapy Improves Functional Outcome in Patients With Progressive Lacunar Strokes"
    Gutierrez, Jose
    STROKE, 2019, 50 (07) : E215 - E215
  • [24] Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial
    Gérard Helft
    Claude Le Feuvre
    Jean Louis Georges
    Didier Carrie
    Florence Leclercq
    Hélène Eltchaninoff
    Alain Furber
    Fabrice Prunier
    Laurent Sebagh
    Simon Cattan
    Guillaume Cayla
    Eric Vicaut
    Jean-Philippe Metzger
    Trials, 14
  • [25] Apixaban Plus Mono versus Dual Antiplatelet Therapy After Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
    Hess, Connie N.
    James, Stefan
    Wojdyla, Daniel M.
    Lopes, Renato D.
    Liaw, Danny
    Hagstrom, Emil
    Bhatt, Deepak L.
    Husted, Steen
    Goodman, Shaun G.
    Lewis, Basil S.
    Verheugt, Freek W.
    De Caterina, Raffaele
    Ogawa, Hisao
    Wallentin, Lars
    Alexander, John H.
    CIRCULATION, 2014, 130
  • [26] Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial
    Helft, Gerard
    Le Feuvre, Claude
    Georges, Jean Louis
    Carrie, Didier
    Leclercq, Florence
    Eltchaninoff, Helene
    Furber, Alain
    Prunier, Fabrice
    Sebagh, Laurent
    Cattan, Simon
    Cayla, Guillaume
    Vicaut, Eric
    Metzger, Jean-Philippe
    TRIALS, 2013, 14
  • [27] Dual antiplatelet therapy after acute coronary syndromes: no time for a CHANGE
    Capodanno, Davide
    EUROINTERVENTION, 2017, 13 (10) : 1133 - 1135
  • [28] Baseline Stroke Risk and Efficacy of Dual-Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial
    Daghlas, Iyas
    Johnston, S. Claiborne
    Easton, J. Donald
    Kim, Anthony S.
    STROKE, 2024, 55 (02) : 385 - 391
  • [29] Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial
    Mac Grory, Brian
    Piccini, Jonathan P.
    Yaghi, Shadi
    Poli, Sven
    De Havenon, Adam
    Rostanski, Sara K.
    Weiss, Martin
    Xian, Ying
    Johnston, S. Claiborne
    Feng, Wuwei
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (03):
  • [30] Letter by Wu et al Regarding Article, "Dual Antiplatelet Therapy Improves Functional Outcome in Patients With Progressive Lacunar Strokes"
    Wu, Chuanjie
    Zhang, Haiyue
    Ji, Xunming
    STROKE, 2019, 50 (07) : E214 - E214
12345